CALGARY, ALBERTA--(CCNMatthews - April 2, 2007) - Resverlogix Corp. (“Resverlogix”) (TSX:RVX) released today that subsequent to important findings announced last week from numerous presentations at the American College of Cardiology (ACC) meeting in New Orleans, attendees learned that merely increasing HDL is not good enough. The goal for future HDL therapies is ApoA-I/HDL enhancement, a process to increase functional HDL which occurs by increasing endogenous Apolipoprotein (ApoA-l) production.
